Switzerland fast-tracks antiviral medication against Covid-19
Remdesivir has already been granted temporary approval in other countries.
Keystone / Marcel Kusch
The Swiss health authorities have granted approval for the remdesivir drug in “record time” for treating coronavirus patients. The temporary authorisation to widen the use of the antiviral drug will be closely monitored in case of adverse side effects.
This content was published on
2 minutes
swissinfo.ch/mga
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday.
It can now be used for a limited period of time to treat patients suffering from SARS-CoV-2-related pneumonia who also require oxygen.
The drug has been authorized for emergency use in the United States, India, Singapore, South Korea and Japan and has been recommended by the European Medicines Agency to treat coronavirus patients in the EU.
Swissmedic said on Thursday that it had conducted a “careful review in record time” of the drug. Hospital doctors have now been given the green light to administer the treatment. “Adverse reactions to the drug will be closely monitored in order to ensure patient safety,” read a statement.
“The product will also be made available to patients outside approved clinical trials and the approved compassionate use programme while the submitted authorisation application is being reviewed,” it added.
Clinical trials in the US on medicaments containing the active ingredient remdesivir found that the hospital stay of severely affected Covid-19 patients was shortened in almost a third of cases.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Registration opens for Eurovision Song Contest 2025 tickets
This content was published on
Registration for tickets to watch the Eurovision Song Contest 2025, which will be held in the Swiss city of Basel in May 12-17, opened on Monday.
Swiss Federal Railways’ new timetable passes ‘commuter test’
This content was published on
The changeover to a new Federal Railways timetable went smoothly for Swiss commuters on Monday morning. Trains were punctual and no overcrowding was observed, say officials.
Nestlé Waters faces Perrier production stoppage, French media report
This content was published on
Nestlé Waters faces a possible halt to its production of Perrier mineral water in the south of France due to health risks, according to French news reports.
Number of Swiss residents claiming benefits drops again
This content was published on
A total of 249,700 people claimed some form of welfare in Switzerland in 2023, representing a social assistance rate of 2.8% - a level not seen since 2005.
This content was published on
Wood is hardly ever recycled in Switzerland. A study by the Swiss Federal Laboratories for Materials Science and Technology (Empa) shows the recycling rate for wood is just under 8%.
Swiss union criticizes ‘insufficient’ wage increases
This content was published on
The Swiss union organisation Travail.Suisse has given a mixed view on 2025 wage negotiations. It says wage increases in some sectors are insufficient to offset the decline in purchasing power.
Ex-Syrian vice-president Rifaat al-Assad could avoid trial in Switzerland
This content was published on
The case against Rifaat al-Assad, the uncle of ousted President Bashar al-Assad who is due to be tried by the Swiss Federal Criminal Court for war crimes and crimes against humanity, could be dropped.
Survey: 82% of Swiss want to ban mobile phones in schools
This content was published on
The vast majority of Swiss residents (82%) want to ban mobile phones in schools, according to a survey published on Sunday. Even young people support the measure.
Swiss Re boss warns of ‘trust deficit’ after killing of UnitedHealth CEO
This content was published on
The murder of UnitedHealth Group executive Brian Thompson in the US and sympathy for the crime are worrying signs for insurers, according to Swiss Re CEO Andreas Berger.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Sixteen Swiss hospitals take part in coronavirus global Solidarity trial
This content was published on
Some 1,000 patients in Switzerland are expected to participate in trials of experimental treatments for Covid-19 as part of global Solidarity trial.
Fight over rights to Covid-19 drugs puts Switzerland in a tough spot
This content was published on
As calls mount for equitable access, Switzerland is caught between established practice and global solidarity in how to encourage medical innovation.
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Novartis steps up coronavirus fight as part of new collaboration
This content was published on
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation in response to the coronavirus pandemic.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Covid-19 is both threat and opportunity for Swiss biotech
This content was published on
Although the coronavirus pandemic is the Swiss biotech industry’s time to shine, it has left many smaller firms struggling to survive.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.